Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma ...
Bcl-2 family proteins are highly conserved molecules that play a crucial role in regulating the release of apoptotic proteins from mitochondria. They possess Bcl-2 homology (BH) domains, which are ...
Use of tumor-mediated TRAIL-receptor expression to evaluate apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer. SPARC microenvironment signature (SMS) in patients ...
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it. The ...
China’s National Medical Products Administration approved Ascentage Pharma Group Corp. Ltd.’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) for treating adults with chronic lymphocytic ...
Multimodal treatment of nodal localizations from Merkel cell carcinoma with no identifiable primary site and distant metastases. Background: Mebendazole (MBZ), a microtubule binding agent, is a potent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results